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Synaptic Activity and Ab Release
Accumulation of b-amyloid protein (Ab) in the extra-
cellular space of the brain has been hypothesized to
be a culprit in the pathogenesis of Alzheimer’s dis-
ease. In this issueofNeuron, Cirrito et al. describe a se-
ries of experiments demonstrating that extracellular
Ab levels are directly modulated by neuronal and syn-
aptic activity.
Alzheimer’s disease, the most common form of demen-
tia in the elderly, is a progressive neurodegenerative dis-
order characterized by a number of pathological fea-
tures including extracellular deposits known as senile
plaques. Beyond postmortem characterization, however,
the pathogenesis of Alzheimer’s disease is still unclear
in many respects. One of the most likely culprits under-
lying Alzheimer’s disease is the b-amyloid protein (Ab),
acting through the amyloid cascade hypothesis. For
example, fibrillar Ab is the primary component of the
plaques that ravage the brains of Alzheimer’s disease
patients. Additionally, Alzheimer’s pathology invariably
develops in those carrying an extra copy of the amyloid
precursor protein (APP) gene (as is present in those with
trisomy 21). Finally, a number of familial genetic muta-
tions have been found that result in early-onset Alz-
heimer’s disease. In these families, alterations in either
APP or in the proteins known to cleave APP (presenilins,
for example) have in common the function of increasing
the production of Ab or the more amyloidogenic and pu-
tatively more toxic Ab42 species.
While the precise mechanisms by which Ab exerts its
pathogenic effects are not clear, a number of key princi-
ples have emerged. For example, much research has fo-
cused on the idea that Ab may exert deleterious effects
on synaptic function—effects that occur before outright
cell death. Changes in the density of synaptophysin, as
a marker of synaptic number, are better correlated with
disease progression than plaque load or cell death (Terry
et al., 1991). In transgenic mouse models of amyloid de-
position, numerous groups have shown deficits in elec-
trophysiological measures of synaptic communication
or plasticity (for example, Hsia et al., 1999), which can
be reversed when amyloid load is lowered by passive im-
munization. Lastly, and most recently, the importance of
the aggregation state of Abhas become apparent; for ex-
ample, soluble Ab oligomers appear to be a necessary
component in the Ab-induced inhibition of long-term po-
tentiation (Klyubin et al., 2005).
Evidence suggests that the concentration of Ab in the
extracellular space plays an important role in the aggre-
gation state and therefore the toxicity of the Ab protein
(Meyer-Luehmann et al., 2003). Thus, given the appar-
ent neurotoxic and synaptotoxic effects of Ab, factors
that influence the production or clearance of Ab, which
in turn contribute to the overall levels of extracellular
Ab in brain, are of obvious importance. In this issue ofNeuron, Cirrito et al. (2005), in a technological tour de
force, examine a promising angle of research in this
direction—the idea that neuronal activity plays a causal
role in determining the levels of extracellular Ab. A role
for neuronal activity in Ab release has previously been
demonstrated (Kamenetz et al., 2003); however, ade-
quate gauging of both the anatomical and temporal
components involved in neuronal activity-induced Ab
accumulation has not previously been attempted. With
the use of a combination of in vivo microdialysis, elec-
trophysiological recording, and in vivo pharmacology,
Cirrito et al. were able to address the dynamic changes
of extracellular Ab levels in response to neuronal stimu-
lation in awake, behaving mice as well as in hippocam-
pal slice preparations.
In their first experiment, Cirrito et al. stimulated the
perforant pathway (the major afferent axon route leading
from the entorhinal cortex into the hippocampus) while
recording electrophysiological activity in the hippocam-
pus and, at the same time, sampling interstitial fluid (ISF)
via microdialysis. Continuous perforant pathway stimu-
lation, which caused epileptiform activity within the hip-
pocampus, caused ISF Ab to increase by 30% within
1 hr, demonstrating a direct relationship between neuro-
nal activity and ISF Ab. Conversely, infusion of tetrodo-
toxin (TTX), which blocks sodium channels and causes
a cessation of neuronal activity, significantly decreased
basal electrophysiological activity and dropped Ab lev-
els by 40%. Importantly, this effect was reversible, sig-
naling a direct causal relationship between neuronal
activity and ISF Ab levels. Furthermore, the drop in Ab
accumulation was shown to be a result of synaptic re-
lease, rather than broad neuronal activity. Infusion of tet-
anus toxin, which inhibits synaptic vesicle release, had
only a small effect on EEG amplitude, but Ab levels de-
creased by 70%—an even greater decline than following
TTX treatment.
While these findings and others like them appear to
confirm that neuronal, and, in particular, synaptic activ-
ity does increase the concentration of extracellular Ab,
the question remains as to the mechanism by which Ab
is increasing. Two possibilities appear likely: first, the
half-life of extracellular Ab may be extended; or second,
there could be an effect on intracellular APP processing.
Using a g-secretase inhibitor (blocking new generation
of Ab) in TTX and vehicle-treated mice, Cirrito et al.
showed that Ab half-life was unaltered by depression
of neuronal activity. Additionally, expression of the Ab-
degrading enzyme neprilysin was unchanged in TTX-
treated mice. Support for the latter possibility (APP pro-
cessing changes) was provided by Kamenetz et al.
(2003). In the Cirrito et al. study, though, TTX-induced
reduction in extracellular Ab did not result in changes
in b-CTF levels. There was a significant 13% increase
in a-CTF level; however, this increase is unlikely to ex-
plain the much larger change in Ab levels.
In order to further investigate this discrepancy and
elucidate the mechanism underlying neuronal activity-
induced Ab alterations, Cirrito et al. treated hippocam-
pal slices with several compounds: a-latrotoxin, which
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874induces synaptic vesicle release in the absence of pre-
synaptic depolarization, and/or a neuronal activity inhib-
itor cocktail containing both presynaptic and postsyn-
aptic activity inhibitors. These experiments confirmed
that synaptic release, even in the absence of neuronal
activity, increases extracellular Ab levels. These changes
were again independent of alterations in CTF levels,
however, indicating that, at least in this time frame, extra-
cellular Ab modulation appears to be directly related to
synaptic vesicle release rather than via changes in Ab
clearance or APP processing.
The results presented in the Cirrito et al. study have
confirmed the general tenet espoused by Kamenetz
et al. (2003) and several other groups—that neuronal or
synaptic activity can directly influence Ab levels. With
this finding well supported, the more relevant question
appears to be related to the mechanism proposed to
underlie this effect. In the Kamenetz et al. study, increas-
ing neuronal activation via a 36 hr picrotoxin treatment
caused a significant increase in secreted Ab that was ac-
companied by a 3-fold increase in b-CTF expression.
Conversely, TTX-treated neurons showed a 50% de-
crease in Ab and an associated drop in b-CTF expres-
sion. The results thus suggested that the level of BACE
cleavage could be controlled by neuronal activity. This
change could be due to an alteration in BACE activity it-
self. Alternatively, if one assumes that BACE cleavage
can take place within axon terminals, increased mem-
brane recycling following neuronal activity would lead
to a greater amount of APP available for processing.
Interestingly, the results of the present study suggest
that rather than requiring changes in APP processing,
synaptic activity-dependent Ab alterations are accom-
plished via a mechanism related specifically to vesicle
release. Specifically, b-CTF levels were unchanged fol-
lowing either TTX treatment (reducing neuronal activity)
or a-latrotoxin treatment (inducing synaptic release),
suggesting that altered BACE-dependent activity is not
required or responsible for the increased extracellular
Ab following synaptic activity. The apparent discrep-
ancy between the present study and the Kamenetz
et al. study may be explained by differences in the treat-
ment regimen. Whereas Kamenetz et al. treated brain
slices with picrotoxin or TTX for 36 hr, inducing changes
in b-CTF expression, in the present study treatments
were shorter and more anatomically localized in the in
vivo setting (16 hr via hippocampal infusion) and much
shorter in hippocampal slices (2 hr). The effect of neuro-
nal activity on BACE cleavage of APP may thus be de-
pendent on time or area of exposure.
In the absence of BACE cleavage alterations and
apparently new Ab generation, where is all of this Ab
coming from? Given that Ab appears to be released syn-
aptically (both neuronal activity and induced vesicular
release cause increases in Ab), one distinct possibility
is that axon terminals may contain a readily releasable
pool of Ab, much like neurotransmitter residing within
synaptic vesicles at presynaptic terminals. What com-
partment, presumably vesicular in nature, Ab is residing
in is unclear. To date, neither APP nor Ab is known to be
sorted into synaptic vesicles (Marquez-Sterling et al.,
1997). Thus, these vesicles are apparently distinct
from neurotransmitter-containing synaptic vesicles yet
respond in an exocytic manner secondary to synapticstimulation. If this hypothesis is correct, it is also inter-
esting to speculate whether synaptic Ab release would
undergo ‘‘fatigue’’ in the same way that neurotransmitter
release can be hindered by overstimulation. However,
whether one can measure release of Ab in the time frame
necessary to answer this question is an understandably
dubious endeavor.
A neuronal origin of Ab is generally accepted. This is
best seen by the dramatic loss of amyloid deposits in
brain following transection of corresponding axonal
tracts (Lazarov et al., 2002). However, it remains unclear
whether Ab is formed upon leaving the cell body, en-
route in axons, or at the presynaptic terminals. Thus,
the synaptic release of Ab from an apparently readily re-
leasable pool has potential implications on the site of Ab
generation within neurons. On the surface then, this no-
tion is consistent with the controversial model proposed
by the Goldstein laboratory, wherein Ab may be pro-
duced during axonal transport of APP (Kamal et al.,
2001, Lazarov et al., 2005). One can envision Ab formed
along the axon or originating from the cell body accumu-
lating at the presynaptic terminal until released exocyti-
cally. On the other hand, because BACE and presenilins
are also axonally transported, it is possible that APP is
proteolytically processed into Abwithin a vesicular com-
partment at synaptic terminals that await a stimulus for
exocytic release. Perhaps the interesting observations
in this study will provide the necessary impetus to re-
solve the precise sites of Ab generation in neurons.
In addition to the cellular issues of APP processing
and Ab release, the idea that Ab levels are correlated
to synaptic activity also has interesting implications at
higher levels of examination. For some time, several
lines of inquiry have seemingly pointed to synaptic activ-
ity as a ‘‘good’’ thing in the aging process. For example,
educational level has been negatively correlated with
Alzheimer’s disease likelihood. Similarly, aging individu-
als have been encouraged to ‘‘keep their mind sharp’’ by
doing crossword puzzles, word jumbles, and the like.
Seemingly at odds with these ideas, recent evidence
has shown that the brain regions with the highest basal
activity in terms of metabolic rate—the so-called ‘‘day-
dreaming’’ areas—are also the most prominently af-
fected by Ab plaques (Buckner et al., 2005). These
results offer an explanation as to why certain brain re-
gions are consistently affected in Alzheimer’s patients,
while other regions are not (assuming that basal meta-
bolic increases are resulting in increased extracellular
Ab accumulation). So, is synaptic activity a good thing
or a bad thing? The question may hinge on whether
one is talking about acute activity (such as in the present
study) or long-term activity. One possibility that might
explain the apparent paradox is that mental activity
(such as working crossword puzzles., etc.) may serve
to activate memory circuits in the short term, but could
perhaps decrease basal activity in these same circuits
in the long term—thus providing a protective effect
against the activity-driven release of Ab.
Perhaps the most important question remaining unan-
swered is: does this transient pool of synaptically re-
leased Ab modulated by brain activity play a role in the
pathogenesis of Alzheimer’s disease? While technolog-
ically remarkable and theoretically intriguing, the pres-
ent study does achieve results in a nonphysiological
knockin mice have similar phenotypes, which sug-
gests that themutant torsinA allele causes disease be-
cause it has decreased function. The experiments also
highlight the possible role of nuclear envelope dynam-
ics in maintaining normal neuronal function.
Many neurological diseases have variants that are
caused by gene defects. The relationships between
Mendelian forms of disease and their sporadic counter-
parts can be debated, but there is a chance of under-
standing the basic pathways leading to neuronal dys-
function. However, the usefulness of this information is
predicated on understanding how the mutation ‘‘works’’
in a genetic sense. For example, a recessive mutation is
usually associated with loss of function, which could be
tested experimentally if one has an assay for the protein
activity. Dominant mutations may work in any number of
ways, by increasing the activity of the protein, introduc-
ing a new toxic property to the protein such as protein
misfolding (gain of novel function), or acting to reduce
the activity of the endogenous protein (dominant nega-
tive). These distinctions are critical for designing the
right experiment to test hypotheses about how diseases
are caused and misapplication really causes problems
in interpretation. Such information may also change
how we design therapeutic strategies and hence is of
significant interest.
The genetics of the human dystonias are complicated
as there are at least 15 extant loci with different pheno-
typic presentations (Klein, 2005). The first identified
gene was named torsinA by Ozelius and colleagues
and is associated with early-onset torsion dystonia
(Ozelius et al., 1997). All torsinA-related dystonia cases
found so far are due to the deletion of one of a pair of glu-
tamate residues (E302/303) toward the C terminus of the
encoded protein. TorsinA is part of the large AAA+ family
of ATPases and the glutamate deletion is near to the ATP
binding region. An interesting aspect of the genetics of
torsinA dystonia is that there is greatly reduced pene-
trance. About one third of patients who carry the causal
DE302/303 mutation go on to develop disease, the rest
remaining asyptomatic. It is also worth noting that the
there appears to be a time-dependent window for sus-
ceptibility. Generally, mutation carriers who are asymp-
tomatic in their early 20s remain so throughout life, al-
though there may be exceptions (Bressman et al.,
2000). This implies that there is a critical timing for the
expression of symptoms, also implying that dystonia is
a developmental disease.
The interpretation of this human genetic evidence is
not simple because there are multiple reasonable ex-
planations for both the low penetrance dominant dis-
ease and the developmental effects. The study by
Goodchild et al. is important because it addresses this
problem in a careful but direct manner. The question
posed by the experiments is: how closely does the
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875manner. For example, Ab enhancement was achieved by
induction of epileptic seizure activity in the hippocam-
pus. One might assume, therefore, that patients with ep-
ilepsy would be at higher risk of Ab accumulation; how-
ever, that has proven not to be the case. Instead, this
model of transient increase in Ab release may be closer
to that seen following traumatic brain injury, a known
risk factor for AD, where there is a brief rise in Ab levels
detected in brain and cerebrospinal fluid (Chen et al.,
2004). In turn, this is correlated to formation of diffuse
amyloid deposits in the brain. Notably, while the physio-
logical relevance of synaptically released Ab is not
completely understood at present, the fact that pharma-
cological inhibition of synaptic vesicle release can de-
crease extracellular Ab by nearly 90% is certainly strong
evidence that this pool of Ab is a potentially significant
source of Ab. Future studies will undoubtedly shed
more light on its functional importance.
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Mutations in torsinA cause dominantly inherited early-
onset torsion dystonia in humans. In this issue ofNeu-
ron, Goodchild et al. show that torsinA knockout and
DE302/303 mutation resemble a loss of function allele?
The authors address this by comparing the phenotypes
of mice with a knockout of torsinA or a knockin mutation
in which one of the pair of glutamate residues is re-
moved. If the two mice are similar in phenotype, this
would argue quite strongly and in a relevant in vivo
context, that the mutation causes a loss of function.
